Hairy cell leukemia
Other Names for this Disease
- Leukemic reticuloendotheliosis
RDCRN 3rd Conference on Clinical Research for Rare Diseases, Tuesday, October 02, 2012
Location: Hilton Washington DC/Rockville Hotel & Executive Meeting Center, Rockville, MD
Description: Clinical research in rare diseases presents a number of challenges and unique issues that are not usually considered in the training of clinical investigators through existing training programs. Goals of the conference include: direct instruction of trainees and new investigators in rare disease research methodology; development of a reusable curriculum/syllabus on rare disease research methodology; and stimulation of ideas regarding the unique issues facing investigators engaged in the study of rare diseases.
Overcoming Barriers to International Clinical Trials for Rare Cancers , Friday, December 10, 2010
Location: Bethesda, Maryland
Description: The goals of this conference were to introduce key institutional players to the topic of international clinical trials in rare cancers and to establish an ongoing dialogue. Participants left the meeting with a set of specific priorities that need to be enacted to promote these trials. The meeting promoted consensus on the way that resources are prioritized to address rare cancers. Participants were asked to convey the content of the meeting to their constituencies and to follow up with pilot concepts.
Treatment of Hairy Cell Leukemia in its Second Half-Century, Monday, April 26, 2010 - Tuesday, April 27, 2010
Location: Wilson Hall (Building 1), 3rd floor, Bethesda, MD
Description: Goals of this conference were to (1) disseminate current knowledge of the standard treatment of hairy cell leukemia (HCL); (2) identify the evidence (or lack thereof) on which current treatment practices are based; (3) determine needs and opportunities for clinical research to improve HCL treatment; (4) disseminate results of newer diagnostic techniques, including flow cytometry, polymerase chain reaction (PCR), and serum markers, to allow decreased reliance on bone marrow biopsy; (5) discuss recent advances in HCL biology, including the molecular characterization of HCL cells with implications for disease origination/prognosis; (6) discuss new treatments for relapse/refractory disease, including investigational agents; (7) improve patient access to treatment and clinical trials; and (8) discuss the evolving activities of the HCL Consortium, including establishing a new HCL Web site to improve access to knowledge, care givers, treatment, and clinical trials. For additional information please contact Dr. Robert Kreitman at email@example.com
VI International Conference on Rare Diseases and Orphan Drugs (ICORD 2010): Global Approach to Accessibility in Rare Diseases, Orphan Drugs and Neglected Diseases , Thursday, March 18, 2010 - Saturday, March 20, 2010
Location: Palais Rouge Convention Center, Palermo, Buenos Aires, Argentina
Description: For the first time, the VI International Conference on Rare Diseases and Orphan Drugs (ICORD 2010) was convened in the southern hemisphere in agreement with its aim of globalization of rare diseases research and orphan products development activities.